在成年人中,每周一次的塞马格卢提德与安慰剂相比,骨折风险增加:一个随机,双盲,双中心的第二阶段试验
Morten S Hansen1,2, Eva M Wölfel2, Shakespeare Jeromdesella1,2
1Department of Endocrinology, Odense University Hospital, Denmark.
EClinicalMedicine
|May 13, 2024
概括
塞马格卢提德并没有增加成年人骨折风险的骨形成. 该药物还增加了骨质再吸收,降低了骨矿物质密度,可能是由于体重减轻.
科学领域:
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1 (GLP-1) 受体激动剂 (GLP-1RAs) 可能影响骨形成和骨折风险.
- 塞马格卢提德是一种GLP-1RA,可能对骨健康产生影响.
研究的目的:
- 评估塞马格卢提德对骨形成标记物Procollagen类型I N-终端 (PINP) 的影响.
- 为了评估塞马格卢提德对骨代谢的影响,在成年人中骨折风险增加.
主要方法:
- 一个随机的,安慰剂控制的,双盲的,第二阶段临床试验.
- 64名患有骨折风险增加的成年人每周一次接受1.0毫克或安慰剂的皮下塞马格卢提德,持续52周.
- 主要结局:从基线到第52周的血 (P) -PINP变化.
主要成果:
- 与安慰剂相比,塞马格卢提德并没有显著改变P-PINP水平.
- 随着塞马格卢提德的使用,观察到骨再吸收标记物 (P-CTX) 的血水平增加.
- 腰椎和部总骨矿物质密度 (aBMD) 在半氨酸组较低.
- 在塞马格卢提德组中观察到显著的体重减轻.
结论:
- 塞马格卢提德并没有增强成年人骨形成,骨折风险增加.
- 增加的骨质吸收和减少的aBMD可能与塞马格卢提德诱导的体重减轻有关.
相关概念视频
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...


